Venetoclax in Combination with Busulfan for High-Risk AML/MDS
Phase 2/3
324
about 6.2 years
18–70
1 site in TX
What this study is about
This trial is testing whether adding venetoclax to the standard treatment of busulfan, cladribine, and fludarabine improves outcomes for adults with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing stem cell transplant. The goal is to see if this combination can better control these cancers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Busulfan
- 2.Take Cladribine
- 3.Take Fludarabine Phosphate
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
busulfan, cladribine, Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), thiotepa, venetoclax
injection, intravenous, injection (Injection), oral
Primary: 1-year progression free survival (PFS)
Secondary: Graft-versus (vs.)-host disease-free, relapse-free survival (GRFS), Incidence of adverse events, Overall survival (OS)
Oncology